F-1/A: Haoxi Health Technology Files for Unit Offering with Warrants

Haoxi Health Technology plans to offer units consisting of Class A Ordinary Shares and warrants to raise capital.

Summary

• Haoxi Health Technology Limited has filed a registration statement for a unit offering.
• Each unit comprises one Class A Ordinary Share (or a pre-funded warrant), one Series A warrant, and one Series B warrant.
• The pre-funded warrants are exercisable upon issuance at $0.0001 per share.
• The Series A warrants are exercisable upon issuance at $3.46 per share, subject to adjustments.
• The Series B warrants are exercisable after the Series B Exercise Date at $0.0001 per share.
• The exercise price of the Series A Warrant shall be adjusted to $0.692 on the Series B Exercise Date.
• The maximum number of Class A Ordinary Shares underlying the Series A Warrants and Series B Warrants would be approximately 18,063,584 shares and 14,450,868 shares, respectively, assuming an offering price of $3.46 per Unit.
• EF Hutton LLC is the underwriter for the offering and has a 45-day option to purchase up to 15% additional units to cover over-allotments.
• The company intends to file with the CSRC within three working days after the completion of this offering.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, outlining the terms of the unit offering. The sentiment is neutral, with a slight positive leaning due to the potential for growth and expansion with the raised capital, but tempered by the inherent risks and uncertainties associated with the company and its operating environment.

Positives

• The offering provides Haoxi Health Technology with additional capital.
• The warrants may incentivize future investment in the company if the share price increases.
• The company has engaged EF Hutton LLC as the underwriter.

Negatives

• There is no established trading market for the Units or the Warrants.
• The offering may cause dilution to existing shareholders.
• The company is subject to regulatory risks associated with operating in China, including potential intervention by the PRC government.
• The company is subject to the Overseas Listing Trial Measures for filing procedures with the CSRC in connection with this offering.

Risks

• The company's operations are subject to legal and operational risks associated with business operations in China.
• The PRC government could disallow the company's corporate structure.
• The CSRC filing procedures could limit the company's ability to offer securities to investors.
• The company may be prohibited from trading on a national exchange under the HFCA Act if the PCAOB cannot inspect the company's auditors.
• The company is dependent on receipt of funds from its PRC subsidiary, Haoxi Beijing, which may be limited by PRC regulations.
• The company may be treated as a resident enterprise for PRC tax purposes.
• The company faces uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises.
• The company is exposed to concentration risk, due to its reliance on its major supplier, Ocean Engine.

Future Outlook

The company intends to use the proceeds from this offering for working capital and general corporate purposes, acquiring or investing in technologies, solutions or businesses that complement our business, and hiring experienced employees to improve our systems of internal control and compliance with U.S. GAAP and the Sarbanes-Oxley Act of 2002.

Industry Context

The announcement reflects a company in the online marketing and digital advertising space seeking capital to expand its operations, a common trend in the tech industry. The focus on the healthcare industry suggests a niche strategy.

Comparison to Industry Standards

• Comparable companies raising capital through unit offerings with warrants include micro-cap and small-cap companies in sectors like biotechnology, technology, and energy.
• The specific terms of the warrants (exercise price, expiration date, and adjustment clauses) are typical for these types of offerings, designed to incentivize future investment while providing immediate capital.
• The underwriter's discount of 7% is within the typical range for similar offerings by smaller companies.

Stakeholder Impact

• Shareholders may experience dilution.
• The company's ability to expand its business and improve its financial performance could benefit employees and customers.
• The offering could increase the company's visibility and access to capital markets.

Next Steps

• Complete the unit offering.
• File with the CSRC within three working days after the completion of this offering.
• Utilize the net proceeds for working capital, acquisitions, and improving internal controls.

Key Dates

Keywords

warrant, offering, shares, Haoxi, CSRC, units, exercise, Series A, Series B, China